Atherothrombosis research
Atherothrombosis is an inflammatory process of the arteries that affects the coronary, cerebral and peripheral circulation.
It is characterized by an aberrant thickening of the vascular wall (atheroma plaque), which reduces blood flow and weakens its structure and can lead to plaque rupture and occlusive thrombus formation (atherothrombosis). This can trigger myocardial infarction, stroke and peripheral arterial disease.
It constitutes one of the main causes of mortality in Spain. It is associated with a poor prognosis and an annual mortality rate of close to 30%. Its development is closely linked to the aging of the population and prevalent risk factors such as diabetes, hypertension, obesity, and smoking, among others.
Need more information?
If you are interested in learning more about our research, please contact us.
We dream of curing atherothrombosis
In recent years, progress has been made in the development of diagnostic tools, but there is still a lack of therapies to slow the progression of the disease, prevent the appearance of thrombosis, and improve the efficient elimination of thrombi.
We deepen our knowledge of the molecular mechanisms that condition the occurrence of thrombotic events and resistance to treatment.
We seek to establish new biomarkers that reflect poor vascular response and thrombus occurrence and to identify new therapeutic targets to prevent the development of atherosclerosis and treat the thrombotic event.
We work closely with researchers and clinicians to rapidly translate laboratory findings to the patient and improve their diagnosis, treatment and prognosis.
REFERENCES IN TRANSLATIONAL RESEARCH
Atherothrombosis Research Group
Reference team in preclinical research on the most relevant inflammatory, proteolytic and prothrombotic mechanisms that lead to the progression of atherosclerosis and thrombus formation with the aim of identifying new therapies and therapeutic targets to optimize diagnosis, develop new treatments and improve the prognosis of patients with atherothrombotic cardiovascular disease.
It is part of the Cardiovascular Disease Program.